belief that Ohtuvayre's bronchodilator and non-steroidal anti-inflammatory activity can re-define the COPD treatment paradigm." The encouraging sales figures come at a time when treatment options ...

Dupixent becomes the first-ever targeted therapy for patients with COPD, the first biologic for the disease, and the first new treatment approach in Europe in over a decade. It has been cleared ...

The medication is approved for use alone or alongside other COPD treatments. Two clinical trials show that Ohtuvayre improved lung function and reduced flare-ups by 40% in patients with moderate to ...

In acute infective exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD), adding erdosteine to standard treatment significantly modified the outcome by improving the ...

chronic obstructive pulmonary disease (COPD), and ... How a New Gut Microbe Drives the Gut-Lung Axis Dec. 19, 2024 — A team has discovered a new communication pathway between the gut and lung.

2010;67(13):1061-1069. Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations. The data of deJong et al. [30] showed no ...

COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment ...

If you’re looking for a cannabidiol (CBD) product to soothe your aches and pains, a topical CBD — such as a CBD cream — may be particularly useful. But how can you tell which CBD creams are ...

However, the researchers also tested for weight loss outcomes. People in the treatment group lost an average of about 8% of their body weight—about 16 pounds—at the highest dose. The company said the ...

I am also involved in studies on the effects of asthma and its treatment on endogenous steroids as well as pharmacoepidemiological studies with focus on asthma and COPD. Furthermore, I'm involved in ...

We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...